CN1303066C - 2－氧代－1－吡咯烷衍生物、其制备方法和用途 - Google Patents

2－氧代－1－吡咯烷衍生物、其制备方法和用途 Download PDF

Info

Publication number
CN1303066C
CN1303066C CNB2005100713086A CN200510071308A CN1303066C CN 1303066 C CN1303066 C CN 1303066C CN B2005100713086 A CNB2005100713086 A CN B2005100713086A CN 200510071308 A CN200510071308 A CN 200510071308A CN 1303066 C CN1303066 C CN 1303066C
Authority
CN
China
Prior art keywords
oxo
pyrrolidinyl
butanamide
pure
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2005100713086A
Other languages
English (en)
Chinese (zh)
Other versions
CN1680314A (zh
Inventor
E·迪夫汀
B·肯达
B·拉勒曼德
A·玛塔格纳
P·米歇尔
P·帕索
P·塔拉格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9886259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1303066(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB SA filed Critical UCB SA
Publication of CN1680314A publication Critical patent/CN1680314A/zh
Application granted granted Critical
Publication of CN1303066C publication Critical patent/CN1303066C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CNB2005100713086A 2000-02-23 2001-02-21 2－氧代－1－吡咯烷衍生物、其制备方法和用途 Expired - Fee Related CN1303066C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0004297.8 2000-02-23
GBGB0004297.8A GB0004297D0 (en) 2000-02-23 2000-02-23 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB018054455A Division CN1208319C (zh) 2000-02-23 2001-02-21 2－氧代－1－吡咯烷衍生物、其制备方法和用途

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CNA2005100999524A Division CN1740151A (zh) 2000-02-23 2001-02-21 2－氧代－1－吡咯烷衍生物、其制备方法和用途
CNA2005100999539A Division CN1740150A (zh) 2000-02-23 2001-02-21 2－氧代－1－吡咯烷衍生物、其制备方法和用途

Publications (2)

Publication Number Publication Date
CN1680314A CN1680314A (zh) 2005-10-12
CN1303066C true CN1303066C (zh) 2007-03-07

Family

ID=9886259

Family Applications (5)

Application Number Title Priority Date Filing Date
CNB2005100713086A Expired - Fee Related CN1303066C (zh) 2000-02-23 2001-02-21 2－氧代－1－吡咯烷衍生物、其制备方法和用途
CNA2005100999539A Pending CN1740150A (zh) 2000-02-23 2001-02-21 2－氧代－1－吡咯烷衍生物、其制备方法和用途
CNA2005100999524A Pending CN1740151A (zh) 2000-02-23 2001-02-21 2－氧代－1－吡咯烷衍生物、其制备方法和用途
CNB018054455A Expired - Lifetime CN1208319C (zh) 2000-02-23 2001-02-21 2－氧代－1－吡咯烷衍生物、其制备方法和用途
CNB018055079A Expired - Fee Related CN1179944C (zh) 2000-02-23 2001-02-21 2-氧代-1-吡咯烷衍生物、其制备方法和用途

Family Applications After (4)

Application Number Title Priority Date Filing Date
CNA2005100999539A Pending CN1740150A (zh) 2000-02-23 2001-02-21 2－氧代－1－吡咯烷衍生物、其制备方法和用途
CNA2005100999524A Pending CN1740151A (zh) 2000-02-23 2001-02-21 2－氧代－1－吡咯烷衍生物、其制备方法和用途
CNB018054455A Expired - Lifetime CN1208319C (zh) 2000-02-23 2001-02-21 2－氧代－1－吡咯烷衍生物、其制备方法和用途
CNB018055079A Expired - Fee Related CN1179944C (zh) 2000-02-23 2001-02-21 2-氧代-1-吡咯烷衍生物、其制备方法和用途

Country Status (43)

Country Link
US (12) US6713635B2 (enExample)
EP (8) EP1447399B9 (enExample)
JP (5) JP4081275B2 (enExample)
KR (4) KR100720784B1 (enExample)
CN (5) CN1303066C (enExample)
AT (5) ATE488500T1 (enExample)
AU (5) AU778510B2 (enExample)
BE (1) BE2016C012I2 (enExample)
BG (4) BG65923B1 (enExample)
BR (2) BRPI0108664B8 (enExample)
CA (2) CA2401048C (enExample)
CO (2) CO5280059A1 (enExample)
CU (2) CU23293B7 (enExample)
CY (3) CY1105517T1 (enExample)
CZ (3) CZ304420B6 (enExample)
DE (5) DE60113514T2 (enExample)
DK (3) DK1265862T3 (enExample)
EG (1) EG24375A (enExample)
ES (5) ES2248307T3 (enExample)
FR (1) FR16C1001I2 (enExample)
GB (1) GB0004297D0 (enExample)
HK (2) HK1052516B (enExample)
HU (4) HU229514B1 (enExample)
IL (5) IL150842A0 (enExample)
IS (8) IS2119B (enExample)
LT (1) LTC1265862I2 (enExample)
LU (1) LU92993I2 (enExample)
ME (1) ME00595B (enExample)
MX (2) MXPA02008206A (enExample)
MY (4) MY138966A (enExample)
NL (1) NL300815I2 (enExample)
NO (6) NO324485B1 (enExample)
NZ (1) NZ520448A (enExample)
PL (3) PL213669B1 (enExample)
PT (2) PT1452524E (enExample)
RO (2) RO121597B1 (enExample)
RS (2) RS50455B (enExample)
RU (5) RU2292336C2 (enExample)
SA (2) SA01220027B1 (enExample)
SI (1) SI1265862T1 (enExample)
TW (2) TW200626544A (enExample)
WO (2) WO2001062726A2 (enExample)
ZA (2) ZA200205671B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106866483A (zh) * 2017-02-05 2017-06-20 苏州鹏旭医药科技有限公司 布瓦西坦的晶型c及其制备方法
CN107513031A (zh) * 2016-06-16 2017-12-26 上海医药集团股份有限公司 一种2-氧代-1-吡咯烷手性衍生物的制备方法

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7365093B2 (en) * 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) * 2000-09-29 2004-02-03 Eastman Chemical Company Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same
WO2002067931A1 (en) * 2001-02-23 2002-09-06 Johns Hopkins University Treatment of tics, tremors and related disorders
AU2002329233B2 (en) * 2001-08-10 2007-08-16 Ucb Pharma Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
JP4351909B2 (ja) * 2001-10-08 2009-10-28 ユセベ ファルマ ソシエテ アノニム 薬剤を調製するための、２−オキソ−１−ピロリジン誘導体の使用
US7235579B2 (en) 2001-10-16 2007-06-26 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
AU2003242538A1 (en) * 2002-05-14 2003-11-11 Ucb, S.A. Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
US7504353B2 (en) 2003-01-13 2009-03-17 Ucb Pharma, S.A. Hydrogenation catalysts
EP1517893A2 (en) * 2003-02-03 2005-03-30 Teva Pharmaceutical Industries Limited Process for producing levetiracetam
ES2214147B1 (es) 2003-02-28 2005-10-01 Farma-Lepori S.A. Procedimiento de obtencion de un agente antiepileptico.
US20050143445A1 (en) * 2003-03-18 2005-06-30 Parthasaradhi Reddy B. Novel crystalline forms of levetiracetam
RU2232578C1 (ru) * 2003-04-10 2004-07-20 Ахапкина Валентина Ивановна Вещество, обладающее антидепрессивной активностью
AU2004232958A1 (en) 2003-04-16 2004-11-04 F.-Hoffmann La-Roche Inc. 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
US7034051B2 (en) * 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
EP1663968A1 (en) * 2003-09-05 2006-06-07 Ranbaxy Laboratories Limited Process for the preparation of pure levetiracetam
JP4658937B2 (ja) * 2003-09-24 2011-03-23 ユセベ ファルマ ソシエテ アノニム ２−オキソ−１−ピロリジン誘導体の製造方法
JP2007513105A (ja) 2003-12-02 2007-05-24 ユ セ ベ ソシエテ アノニム イミダゾール誘導体、その製法及び使用
CA2568700A1 (en) * 2004-06-11 2005-12-22 Ucb, S.A. Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
CN102102114B (zh) * 2004-06-21 2013-08-14 沃尼尔·朗伯有限责任公司 普瑞巴林和相关化合物的制备
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
WO2006044955A1 (en) * 2004-10-20 2006-04-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
CA2488325C (en) * 2004-11-22 2010-08-24 Apotex Pharmachem Inc. Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
EP1912966A2 (en) 2005-06-01 2008-04-23 Ucb, S.A. 2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
CA2620243C (en) * 2005-09-15 2015-01-20 Ucb Pharma, S.A. 4-substituted pyrrolidin-2-ones and their use
JP2007153755A (ja) * 2005-12-01 2007-06-21 Gifu Univ プロリン類縁体
AU2006322297A1 (en) * 2005-12-07 2007-06-14 Ucb Pharma, S.A. 3-carboxy- 2-oxo-1 -pyrrolidine derivatives and their uses
US8338621B2 (en) 2005-12-21 2012-12-25 Ucb S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
LV13630B (en) * 2006-03-16 2007-12-20 Olainfarm As Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone
CN101506157B (zh) * 2006-06-08 2013-07-24 Ucb医药有限公司 吡咯烷酮共结晶
WO2007144195A2 (en) 2006-06-15 2007-12-21 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
DK2076508T3 (da) * 2006-10-18 2011-02-21 Pfizer Prod Inc Biaryl-ether-urinstof-forbindelser
US8828665B2 (en) 2007-02-16 2014-09-09 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
EP2152262A2 (en) * 2007-04-27 2010-02-17 UCB Pharma, S.A. New heterocyclic derivatives useful for the treatment of cns disorders
US20090082422A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched levetiracetam
PT2273975E (pt) * 2008-03-03 2014-07-17 Ucb Pharma Sa Processos de preparação e utilizações terapêuticas de soluções farmacêuticas
US7741327B2 (en) * 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
WO2010002869A1 (en) * 2008-07-01 2010-01-07 Concert Pharmaceuticals, Inc. 2-oxo-1-pyrrolidine derivatives
EP2147911A1 (en) 2008-07-24 2010-01-27 ZaCh System S.p.A. Process for the preparation of levetiracetam
JP4644881B2 (ja) 2008-09-19 2011-03-09 高砂香料工業株式会社 ルテニウム錯体の製造方法
ES2865504T3 (es) 2008-10-16 2021-10-15 Univ Johns Hopkins Procedimientos y composiciones para la mejora de la función cognitiva
EP2349335B1 (en) 2008-10-24 2013-08-07 ARK Diagnostics, Inc. Levetiracetam immunoassays
US8722715B2 (en) * 2008-11-07 2014-05-13 NovaBay Pharmaceuticals Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions
EA019583B1 (ru) * 2008-11-18 2014-04-30 Юсб Фарма, С.А. Композиции с пролонгированным высвобождением, содержащие производное 2-оксо-1-пирролидина
PL2358360T3 (pl) * 2008-11-18 2017-02-28 Ucb Biopharma Sprl Preparaty o przedłużonym uwalnianiu zawierające pochodną 2-okso-1-pirolidyny
FR2939311A1 (fr) * 2008-12-08 2010-06-11 Oreal Utilisation d'un derive diester de pyrrolidinone 4-carboxy comme solvant dans les compositions cosmetiques ; compositions cosmetiques les contenant
WO2010089372A1 (en) 2009-02-09 2010-08-12 Ucb Pharma, S.A. Pharmaceutical compositions comprising brivaracetam
US8846411B2 (en) * 2009-06-11 2014-09-30 Microgenics Corporation Derivatives, reagents, and immunoassay for detecting levetiracetam
EP2461808A2 (en) 2009-08-07 2012-06-13 UCB Pharma S.A. Methods for enhancing the cognitive function
US7939676B2 (en) 2009-09-17 2011-05-10 Zach System S.P.A. Process for the preparation of levetiracetam
US8487591B1 (en) 2009-12-31 2013-07-16 Cirrus Logic, Inc. Power control system with power drop out immunity and uncompromised startup time
HUE028668T2 (en) * 2009-10-23 2016-12-28 Ucb Biopharma Sprl 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives
PL389364A1 (pl) 2009-10-23 2011-04-26 Uniwersytet Jagielloński Nowe zastosowanie pochodnych 2-pirolidonu
EA037187B1 (ru) 2010-02-09 2021-02-17 Дзе Джонс Хопкинс Юниверсити Способ и композиция для лечения когнитивного расстройства
FR2961101B1 (fr) 2010-06-09 2013-01-25 Oreal Composition comprenant au moins une 2-pyrrolidone fonctionnalisee par un radical ester ou amide, et au moins un pigment ou un colorant direct pour la teinture des matieres keratiniques
FR2961099B1 (fr) 2010-06-09 2012-06-15 Oreal Derives de 2-pyrrolidone fonctionnalisee par un radical ester, acide ou amide, la composition cosmetique les comprenant et leur utilisation pour le conditionnement des matieres keratiniques
FR2961098A1 (fr) 2010-06-09 2011-12-16 Oreal Composition comprenant au moins une 2-pyrrolidone fonctionnalisee en position 4 par un acide carboxylique ou amide, et au moins un colorant direct ou un pigment pour la teinture des fibres keratiniques
US8466297B2 (en) 2010-11-01 2013-06-18 Milan Soukup Manufacturing process for (S)-Pregabalin
BR112013012062B1 (pt) 2010-11-15 2020-06-02 Agenebio, Inc Composto derivado da piridazina ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso do composto
BR112013020283A2 (pt) * 2011-02-09 2016-07-19 Univ Johns Hopkins "uso de inibidor de proteína de vesícula sináptica 2a (sv2a), valproato, levetiracetam, brivarecetam e seletracetam no tratamento de deficiência cognitiva, bem como composição farmacêutica compreendendo os mesmos"
DK2699581T3 (en) 2011-04-18 2016-01-11 Ucb Biopharma Sprl 2-oxo-1-IMIDAZOLIDINYLIMIDAZOTHIADIAZOLDERIVATIVER
JP6162125B2 (ja) 2011-09-30 2017-07-12 タフツ・ユニバーシティ 神経変性障害を処置するためのウリジン二リン酸誘導体、組成物および方法
EP2797881B1 (en) * 2011-12-27 2018-11-14 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same
TW201408294A (zh) * 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療帕金森氏症之用除
TW201408293A (zh) * 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療疾病相關疲勞之用途
AU2013323188B2 (en) 2012-09-28 2018-04-19 Tufts University Uridine diphosphate derivatives, prodrugs, compositions and uses thereof
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3406594A1 (en) 2012-12-07 2018-11-28 Merck Sharp & Dohme Corp. Biocatalytic transamination process
WO2014087367A2 (en) * 2012-12-09 2014-06-12 Mahesh Kandula Compositions and methods for the treatment of neurological diseases and its associated complications
EP2945942B1 (en) 2013-01-18 2018-05-09 ARK Diagnostics, Inc. Voriconazole immunoassays
ES2674704T3 (es) 2013-02-13 2018-07-03 Ark Diagnostics, Inc. Inmunoensayos de posaconazol
AR095442A1 (es) 2013-03-13 2015-10-14 Univ Tufts Derivados de nucleósido de uridina, composiciones y métodos de uso
AU2014243707B2 (en) 2013-03-13 2018-08-30 Tufts University Uridine nucleoside derivatives, compositions and methods of use
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
CN103342672B (zh) * 2013-07-02 2015-12-23 扬州大学 取代吡咯烷-2-酮的新合成方法
JP6465634B2 (ja) * 2013-12-05 2019-02-06 株式会社日本触媒 環状アミド基含有重合体
JP6453632B2 (ja) * 2013-12-05 2019-01-16 株式会社日本触媒 環状アミドアクリレート含有組成物およびその製造方法
NZ722077A (en) 2013-12-20 2021-12-24 Agenebio Inc Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2015208233B2 (en) 2014-01-21 2019-08-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
CN104098497B (zh) * 2014-06-17 2016-04-13 王庚禹 一种新的酰胺类化合物
WO2016075082A1 (en) 2014-11-10 2016-05-19 Sandoz Ag Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam
WO2016131947A1 (en) 2015-02-20 2016-08-25 Ucb Biopharma Sprl Combination treatment
CN108689968B (zh) * 2015-05-25 2020-09-15 苏州鹏旭医药科技有限公司 两种化合物及其制备方法和在合成布瓦西坦中的用途
CA2984832A1 (en) * 2015-05-25 2016-12-01 Esteve Quimica S.A. Processes to produce brivaracetam
CN106365986B (zh) * 2015-07-21 2019-01-08 苏州鹏旭医药科技有限公司 化合物及其制备方法和在合成布瓦西坦中的用途
CN108026107B (zh) 2015-06-19 2021-07-30 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
EP3954394A1 (en) 2015-06-19 2022-02-16 Centurion BioPharma Corporation Delivery systems for controlled drug release
RS62472B1 (sr) 2015-11-03 2021-11-30 UCB Biopharma SRL Postupak pripreme brivaracetama
WO2017076737A1 (en) 2015-11-03 2017-05-11 Ucb Biopharma Sprl Continuous process for preparing brivaracetam
CN106748748B (zh) * 2015-11-10 2021-08-24 成都国为生物医药有限公司 一种布瓦西坦的制备方法及其中间体
CN105646319B (zh) * 2015-12-30 2018-05-18 佛山市隆信医药科技有限公司 一种布瓦西坦的制备方法
JP6902033B2 (ja) 2015-12-30 2021-07-14 アダマス ファーマシューティカルズ， インコーポレイテッド 発作−関連障害の処置のための方法および組成物
EP3452447A4 (en) 2016-05-03 2019-12-18 The Regents of The University of California INHIBITORS OF IRES-MEDIATED PROTEIN SYNTHESIS
RU2629117C1 (ru) * 2016-06-14 2017-08-24 Сизов Владимир Владимирович Способ получения 4-замещенного 2-[2-оксо-1-пирролидинил] ацетамида
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CA3050255A1 (en) 2017-01-20 2018-07-26 The Regents Of The University Of California Inhibitors of the n-terminal domain of the androgen receptor
WO2018141276A1 (zh) * 2017-02-05 2018-08-09 苏州鹏旭医药科技有限公司 布瓦西坦中间体的晶型a及其制备方法和布瓦西坦的晶型c及其制备方法
CN108503610B (zh) 2017-02-24 2019-09-13 北京艾百诺医药股份有限公司 一种光学纯的(r)-4-正丙基-二氢呋喃-2(3h)-酮的制备方法
CN108658831B (zh) * 2017-03-30 2021-11-05 江苏豪森药业集团有限公司 2-氧代-1-吡咯烷衍生物或其盐的制备方法
MA48475A (fr) 2017-04-24 2020-03-04 Tesaro Inc Procédés de fabrication de niraparib
MX2019015475A (es) 2017-06-30 2020-02-19 Univ California Composiciones y metodos para modular el crecimiento del cabello.
JP2020536855A (ja) 2017-09-26 2020-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療するための組成物及び方法
CN107793342A (zh) * 2017-10-19 2018-03-13 丽珠集团新北江制药股份有限公司 一种布瓦西坦的制备方法
CN107721896A (zh) * 2017-10-19 2018-02-23 丽珠集团新北江制药股份有限公司 一种布瓦西坦的中间体的制备方法
AU2018375787B2 (en) 2017-11-30 2023-02-23 Ladrx Corporation Albumin-binding prodrugs of auristatin E derivatives
EP3717018A1 (en) 2017-11-30 2020-10-07 Centurion BioPharma Corporation Maytansinoid-based drug delivery systems
EP3749640B1 (en) 2018-01-30 2025-07-16 The Regents of the University of California Inhibitors of the wnt/beta-catenin pathway
CN108147988B (zh) * 2018-02-13 2020-10-02 扬州奥锐特药业有限公司 一种高手性纯度内酰胺化合物的制备方法
CN108530402B (zh) * 2018-04-10 2020-06-26 浙江工业大学 一种(R)-3-丙基-γ-丁内酯的制备方法
EP3566760A1 (en) * 2018-05-07 2019-11-13 Universite Libre De Bruxelles Method for nucleating crystals from a solution in a capillary tube
WO2019215062A1 (en) 2018-05-08 2019-11-14 Ucb Biopharma Sprl 1-imidazothiadiazolo-2h-pyrrol-5-one derivatives
IL279530B1 (en) 2018-06-19 2025-09-01 Agenebio Inc Benzodiazepine history, preparations, and methods for treating cognitive disorder
CN110615744B (zh) 2018-06-20 2023-01-06 上海朴颐化学科技有限公司 一种布瓦西坦中间体及其制备方法
WO2020006489A1 (en) 2018-06-29 2020-01-02 The Regents Of The University Of California New molecular tweezers against neurological disorders and viral infections
RU2699669C1 (ru) * 2018-07-04 2019-09-09 Общество С Ограниченной Ответственностью "Валента - Интеллект" Новые составы N-карбамоилметил-4-фенил-2-пирролидона
SG11202100429TA (en) 2018-07-27 2021-02-25 California Inst Of Techn Cdk inhibitors and uses thereof
WO2020081836A1 (en) 2018-10-17 2020-04-23 The Regents Of The University Of California Prodrugs of alpha-ketoglutarate, alpha-ketobutyrate, alpha-ketoisovalerate, and alpha-ketoisohexanoate, and uses thereof
EP3699173A1 (en) 2018-10-18 2020-08-26 California Institute of Technology Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same
BR112021008354A2 (pt) 2018-10-31 2021-08-03 Intocell, Inc. derivados de benzodiazepina heterocíclica fundida e usos dos mesmos
CN113164767A (zh) 2018-12-04 2021-07-23 美蒂斯制药公司 包含非外消旋比例的(r)-2-(2-氧代-1-吡咯烷基)丁酰胺和(s)-2-(2-氧代-1-吡咯烷基)丁酰胺的协同组合物
EP3944739A4 (en) 2019-02-25 2023-06-21 The Regents of the University of California METHOD OF FRAGMENTATION OF CARBON-CARBON BONDS
CN109932442A (zh) * 2019-03-04 2019-06-25 成都美域高制药有限公司 一种布瓦西坦异构体的检测方法
US20220194949A1 (en) 2019-03-25 2022-06-23 California Institute Of Technology Prmt5 inhibitors and uses thereof
JP2022534704A (ja) 2019-06-04 2022-08-03 ヘイガー バイオサイエンシズ，エルエルシー オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法
CN110357752A (zh) * 2019-08-15 2019-10-22 中国工程物理研究院化工材料研究所 一种快速制备均匀包覆含能材料的方法
RU2732245C1 (ru) * 2019-08-30 2020-09-14 Ооо "Валента-Интеллект" Новые составы n-карбамоилметил-4-фенил-2-пирролидона для лечения и профилактики ожирения
CN110551050A (zh) * 2019-09-02 2019-12-10 南通大学 一种2-[3’-(N-Boc-吡咯基)]-苯甲酸的合成方法
US10781170B1 (en) 2019-10-21 2020-09-22 Divi's Laboratories Ltd. Process for preparing Brivaracetam
US20230100559A1 (en) 2020-01-07 2023-03-30 The Trustees Of Princeton University Compositions and Methods for Treatment of Disease by Manipulation of Serine Metabolism
WO2021142221A1 (en) 2020-01-10 2021-07-15 The Regents Of The University Of California Compositions and methods for the treatment of neurodegenerative diseases
US20230174460A1 (en) 2020-04-21 2023-06-08 President And Fellowes Of Harvard College Afmt analogs and their use in methods of treating parkinson's disease
LV15614A (lv) 2020-07-30 2022-02-20 Latvijas Organiskās Sintēzes Institūts 2-(2-okso-3-pirolin-1-il)acetamīdi kā pretkrampju līdzekļi
CA3191166A1 (en) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28
CA3191163A1 (en) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
WO2022035805A1 (en) 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
WO2022076285A1 (en) * 2020-10-06 2022-04-14 D.E. Shaw Research, Llc LACTAM COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS
WO2022087433A1 (en) 2020-10-23 2022-04-28 Dana-Farber Cancer Institute, Inc. Covalent inhibitors of creatine kinase (ck) and uses thereof for treating and preventing cancer
US20240058344A1 (en) 2020-12-18 2024-02-22 Cornell University Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
EP4262880A1 (en) 2020-12-21 2023-10-25 Cornell University Peptide-linked drug delivery system
US20240132480A1 (en) 2021-01-08 2024-04-25 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
US11400074B1 (en) 2021-02-01 2022-08-02 Divi's Laboratories Ltd. Enzymatic process for the preparation of (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and its conversion into brivaracetam
US11384050B1 (en) * 2021-02-03 2022-07-12 Vitaworks Ip, Llc Method for preparing levetiracetam and intermediates thereof
CN114948953A (zh) * 2021-06-29 2022-08-30 四川大学华西医院 一种杂原子取代芳香类化合物及其盐的用途
CN113511994B (zh) * 2021-08-16 2023-03-21 江苏八巨药业有限公司 一种左乙拉西坦的制备方法
CN114634437B (zh) * 2022-03-29 2023-05-30 武汉氟本氘合新材料科技有限公司 一种布瓦西坦的简易制备方法
US11884623B2 (en) 2022-05-23 2024-01-30 Divi's Laboratories Ltd. Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam
WO2023250157A1 (en) 2022-06-24 2023-12-28 Cornell University Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
EP4554939A1 (en) 2022-07-13 2025-05-21 Astrazeneca AB Pcsk9 inhibitors and methods of use thereof
AU2023324882A1 (en) 2022-08-19 2025-03-20 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
JP2025529136A (ja) * 2022-08-31 2025-09-04 コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション キラルガンマラクタム誘導体またはその薬学的に許容可能な塩およびその製造方法
WO2024163711A1 (en) 2023-02-02 2024-08-08 Osmoses Inc. Norbornyl benzocyclobutene ladder polymer composite membranes for fluid separation
CN116041240B (zh) 2023-02-17 2024-04-09 扬州奥锐特药业有限公司 布立西坦中间体的不对称催化氢化合成方法
EP4431086A1 (en) 2023-03-16 2024-09-18 Adalvo Limited Pharmaceutical composition comprising (2s)-2-[(4r)-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl]butanamide
WO2025078883A2 (en) 2023-05-06 2025-04-17 Prepaire Labs Limited Organic compound (oxime) to combat chemical warfare agents
WO2025064475A2 (en) 2023-09-18 2025-03-27 Flagship Pioneering Innovations Vii, Llc Ionizable lipidoid compositions and therapeutic uses thereof
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025072893A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for non-viral gene delivery
TW202535835A (zh) 2023-11-14 2025-09-16 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 可電離類脂質組成物及其治療用途
WO2025231452A1 (en) 2024-05-02 2025-11-06 Martinez Montemayor Michelle Ergosterol peroxide derivatives and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2836599A (en) * 1957-03-07 1958-05-27 Aerojet General Co Nu-(carboxyalkyl) dinitro lactams
GB1309692A (en) * 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
CN1015541B (zh) * 1984-05-15 1992-02-19 尤西比公司 (S)-α-乙基-2-氧代-1-吡咯烷乙酰胺的制备方法
CN1015542B (zh) * 1984-05-15 1992-02-19 尤西比公司 (R)-α-乙基-2-氧代-1-吡咯烷乙酰胺的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD92031A (enExample) *
DE92031C (enExample)
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
US4008281A (en) 1973-12-03 1977-02-15 Monsanto Company Asymmetric catalysis
HU177239B (hu) 1974-10-15 1981-08-28 Monsanto Co Eljárás N-acetamido-L-alanin-származékok előállítására α-acetamido-akrilsav-származékok aszimmetrikus katalitikus hídrogénezésével
EP0089900B1 (en) * 1982-03-24 1985-12-27 Prodes S.A. New n-((2-oxo-1-pyrrolidinyl)acetyl)piperazines, the methods of producing such new compounds and their salts as well as pharmaceutical preparations for therapeutic use containing these compounds or salts
DE3371510D1 (en) * 1982-03-24 1987-06-19 Prodes Sa New 2-oxo-1-pyrrolidineacetic acid esters, their methods of production and therapeutic compositions containing the same
GB8412358D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
JPS60166692A (ja) 1984-09-28 1985-08-29 Kazuo Achinami 新規不斉還元試薬
CH666891A5 (de) * 1985-11-26 1988-08-31 Lonza Ag 4-alkoxy-2-oxo-pyrrolidin-1-yl-essigsaeure-c(1)-c(4)-alkylester, deren herstellung und verwendung.
DE3719873A1 (de) * 1987-06-13 1988-12-29 Basf Ag Verfahren zur herstellung von itaconsaeurediestern und itaconsaeure
JPH0757758B2 (ja) 1988-10-24 1995-06-21 高砂香料工業株式会社 ルテニウム―ホスフィン錯体
GB8827389D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
CA2067614C (en) * 1991-05-02 2002-07-30 Eiichi Otomo Agent for improving dementia
US5171892A (en) 1991-07-02 1992-12-15 E. I. Du Pont De Nemours And Company Chiral phospholanes via chiral 1,4-diol cyclic sulfates
GB9319732D0 (en) 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
EP0645135A1 (de) * 1993-09-29 1995-03-29 Solco Basel AG Hämodialysat enthaltendes Sonnenschutzmittel
JPH1180027A (ja) * 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 向知性薬
TW544311B (en) * 1998-08-06 2003-08-01 Daiichi Seiyaku Co Therapeutic or preventive agent for intractable epilepsies
CZ20001055A3 (cs) * 1998-10-02 2000-08-16 Dupont Pharmaceuticals Company Nové laktamové inhibitory metaloproteázy
YU37602A (sh) 1999-12-01 2005-07-19 Ucb S.A. Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) 2000-09-29 2004-02-03 Eastman Chemical Company Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2836599A (en) * 1957-03-07 1958-05-27 Aerojet General Co Nu-(carboxyalkyl) dinitro lactams
GB1309692A (en) * 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
CN1015541B (zh) * 1984-05-15 1992-02-19 尤西比公司 (S)-α-乙基-2-氧代-1-吡咯烷乙酰胺的制备方法
CN1015542B (zh) * 1984-05-15 1992-02-19 尤西比公司 (R)-α-乙基-2-氧代-1-吡咯烷乙酰胺的制备方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107513031A (zh) * 2016-06-16 2017-12-26 上海医药集团股份有限公司 一种2-氧代-1-吡咯烷手性衍生物的制备方法
CN107513031B (zh) * 2016-06-16 2022-08-02 上海医药集团股份有限公司 一种2-氧代-1-吡咯烷手性衍生物的制备方法
CN106866483A (zh) * 2017-02-05 2017-06-20 苏州鹏旭医药科技有限公司 布瓦西坦的晶型c及其制备方法

Also Published As

Publication number Publication date
NO20023997L (no) 2002-10-22
RU2002124865A (ru) 2004-01-10
FR16C1001I1 (fr) 2016-07-01
MY139420A (en) 2009-09-30
IS7920A (is) 2005-06-29
CY2016022I1 (el) 2016-10-05
DE60113514T2 (de) 2006-05-18
AU2005200717B2 (en) 2007-05-17
AU7389601A (en) 2001-09-12
RU2005125645A (ru) 2007-02-20
US7358276B2 (en) 2008-04-15
ATE282592T1 (de) 2004-12-15
DK1447399T3 (da) 2006-08-28
NO324051B1 (no) 2007-08-06
MEP6109A (en) 2011-12-20
CA2401033C (en) 2008-07-29
US20050171188A1 (en) 2005-08-04
IS2119B (is) 2006-06-15
DE60143493D1 (de) 2010-12-30
CN1740150A (zh) 2006-03-01
TW200626544A (en) 2006-08-01
ATE325093T1 (de) 2006-06-15
WO2001062726A3 (en) 2002-01-17
EP1604979A1 (en) 2005-12-14
ATE445597T1 (de) 2009-10-15
KR100816185B1 (ko) 2008-03-21
NO20023997D0 (no) 2002-08-22
BG65783B1 (bg) 2009-11-30
DE60107216D1 (de) 2004-12-23
MXPA02008056A (es) 2004-08-12
KR100720784B1 (ko) 2007-05-23
IL150757A0 (en) 2003-02-12
IS2754B (is) 2011-09-15
AU2001252144B2 (en) 2005-04-28
US6858740B2 (en) 2005-02-22
BE2016C012I2 (enExample) 2020-01-30
EP1265862A2 (en) 2002-12-18
IL170181A (en) 2010-11-30
PL212197B1 (pl) 2012-08-31
US20040092576A1 (en) 2004-05-13
NO324485B1 (no) 2007-10-29
BRPI0108664B1 (pt) 2016-07-26
HUP0300196A3 (en) 2005-10-28
EP1447399B1 (en) 2006-05-03
PL213669B1 (pl) 2013-04-30
SA01220027B1 (ar) 2006-09-19
CZ304420B6 (cs) 2014-04-30
RU2292336C2 (ru) 2007-01-27
US6911461B2 (en) 2005-06-28
IS7923A (is) 2005-06-29
IS2176B (is) 2006-12-15
US20030040631A1 (en) 2003-02-27
CU23293B7 (es) 2008-06-30
CY2016022I2 (el) 2016-10-05
HUP0300196A2 (hu) 2003-06-28
ME00595B (me) 2011-12-20
HU230270B1 (hu) 2015-11-30
HU229514B1 (en) 2014-01-28
JP2007182459A (ja) 2007-07-19
BG107016A (en) 2003-04-30
ES2355140T3 (es) 2011-03-23
BG65803B1 (bg) 2009-12-31
EP1447399B9 (en) 2006-10-18
HK1052516B (zh) 2006-02-10
NO20023995D0 (no) 2002-08-22
US7217826B2 (en) 2007-05-15
NO2023025I1 (no) 2023-06-20
BR0108657A (pt) 2003-04-29
RS50454B (sr) 2010-03-02
ZA200205671B (en) 2003-11-10
DE60119397T2 (de) 2007-04-19
CU23201A3 (es) 2007-04-06
CO5280059A1 (es) 2003-05-30
RU2005125569A (ru) 2007-02-20
EP1452524A1 (en) 2004-09-01
RO121559B1 (ro) 2007-11-30
BG65923B1 (bg) 2010-05-31
EP1263727A1 (en) 2002-12-11
ES2334998T3 (es) 2010-03-18
RU2006125756A (ru) 2008-01-27
CY1109718T1 (el) 2014-08-13
IS6481A (is) 2002-07-23
IS6472A (is) 2002-07-16
DE60119397D1 (de) 2006-06-08
IL166768A (en) 2010-04-15
AU778510B2 (en) 2004-12-09
US6784197B2 (en) 2004-08-31
ZA200205837B (en) 2003-11-04
US8034958B2 (en) 2011-10-11
EP1577296A1 (en) 2005-09-21
US20040192757A1 (en) 2004-09-30
EG24375A (en) 2009-03-19
PL210121B1 (pl) 2011-12-30
ATE488500T1 (de) 2010-12-15
US20120035239A1 (en) 2012-02-09
RU2291860C3 (ru) 2017-11-16
NO2016005I2 (no) 2016-03-08
MXPA02008206A (es) 2004-04-05
JP4081275B2 (ja) 2008-04-23
CN1404470A (zh) 2003-03-19
US20100222576A1 (en) 2010-09-02
CA2401048C (en) 2009-01-20
IS7919A (is) 2005-06-29
KR20020075926A (ko) 2002-10-07
BR0108664A (pt) 2003-04-29
AU2001252144C1 (en) 2008-03-20
BG107004A (bg) 2003-04-30
WO2001062726A2 (en) 2001-08-30
US8492416B2 (en) 2013-07-23
IS7918A (is) 2005-06-29
DK1452524T3 (da) 2010-03-01
KR20020075927A (ko) 2002-10-07
CY1105517T1 (el) 2010-07-28
EP1477478A2 (en) 2004-11-17
SA01220078B1 (ar) 2006-10-29
NO20023995L (no) 2002-10-21
AU5214401A (en) 2001-09-03
ES2231501T3 (es) 2005-05-16
JP2006022107A (ja) 2006-01-26
YU63102A (sh) 2005-09-19
YU63202A (sh) 2005-09-19
IL150842A0 (en) 2003-02-12
PL359388A1 (en) 2004-08-23
CO5271667A1 (es) 2003-04-30
LTC1265862I2 (lt) 2023-09-11
HUP0204526A3 (en) 2005-03-29
US20050171187A1 (en) 2005-08-04
WO2001064637A1 (en) 2001-09-07
IL166768A0 (en) 2006-01-15
NL300815I2 (enExample) 2016-07-27
EP1477478B1 (en) 2010-11-17
IL150842A (en) 2008-06-05
HUP0204526A2 (hu) 2003-04-28
IS7921A (is) 2005-06-29
RS50455B (sr) 2010-03-02
BG109297A (en) 2006-06-30
US20030120080A1 (en) 2003-06-26
US20050159475A1 (en) 2005-07-21
TW200626545A (en) 2006-08-01
US20040087646A1 (en) 2004-05-06
JP4121744B2 (ja) 2008-07-23
ATE304999T1 (de) 2005-10-15
US6969770B2 (en) 2005-11-29
SI1265862T1 (sl) 2006-02-28
KR20050090090A (ko) 2005-09-12
RO121597B1 (ro) 2007-12-28
JP4938259B2 (ja) 2012-05-23
FR16C1001I2 (fr) 2017-02-03
GB0004297D0 (en) 2000-04-12
EP1577295A1 (en) 2005-09-21
CZ20022850A3 (cs) 2003-02-12
EP1263727B1 (en) 2004-11-17
AU2005200717A1 (en) 2005-03-17
US6806287B2 (en) 2004-10-19
DE60107216T2 (de) 2005-11-03
ES2264060T3 (es) 2006-12-16
EP1265862B1 (en) 2005-09-21
CN1404469A (zh) 2003-03-19
JP2003523996A (ja) 2003-08-12
MY138966A (en) 2009-08-28
KR100759145B1 (ko) 2007-09-14
NZ520448A (en) 2004-03-26
PT1447399E (pt) 2006-09-29
HK1052516A1 (en) 2003-09-19
HK1052695B (zh) 2005-05-06
LTPA2016013I1 (lt) 2016-05-25
AU2005200718B2 (en) 2007-05-24
NO2016005I1 (no) 2016-03-08
DE60113514D1 (de) 2005-10-27
KR100681580B1 (ko) 2007-02-09
EP1447399A1 (en) 2004-08-18
HU0500902D0 (en) 2005-12-28
KR20050091112A (ko) 2005-09-14
DE60140222D1 (de) 2009-11-26
US7692028B2 (en) 2010-04-06
IS7922A (is) 2005-06-29
RU2291860C2 (ru) 2007-01-20
CN1680314A (zh) 2005-10-12
CZ304702B6 (cs) 2014-09-03
HK1052695A1 (en) 2003-09-26
JP2006022108A (ja) 2006-01-26
CZ20022849A3 (cs) 2003-02-12
NO20053645L (no) 2002-10-22
CN1208319C (zh) 2005-06-29
CA2401033A1 (en) 2001-08-30
US20040116507A1 (en) 2004-06-17
CN1179944C (zh) 2004-12-15
CN1740151A (zh) 2006-03-01
MY127149A (en) 2006-11-30
JP4769756B2 (ja) 2011-09-07
PT1452524E (pt) 2010-01-18
JP2003528828A (ja) 2003-09-30
HUS1600017I1 (hu) 2020-02-28
NO20053644L (no) 2002-10-22
AU2005200718A1 (en) 2005-03-17
LU92993I2 (fr) 2016-05-11
US20080097109A1 (en) 2008-04-24
PL365159A1 (en) 2004-12-27
ES2248307T3 (es) 2006-03-16
BRPI0108664B8 (pt) 2021-05-25
MY140593A (en) 2009-12-31
RU2355680C2 (ru) 2009-05-20
EP1477478A3 (en) 2004-11-24
EP1452524B1 (en) 2009-10-14
CA2401048A1 (en) 2001-09-07
DK1265862T3 (da) 2006-01-30
US6713635B2 (en) 2004-03-30

Similar Documents

Publication Publication Date Title
CN1303066C (zh) 2－氧代－1－吡咯烷衍生物、其制备方法和用途
CN1203047C (zh) 用作一元胺重摄取抑制剂的联芳醚衍生物
CN1604776A (zh) 作为用于治疗神经病综合症的pde－4抑制剂的4－(4－烷氧基－3－羟基苯基)－2－吡咯烷酮衍生物
CN1805929A (zh) 磷酸二酯酶4抑制剂
CN1859904A (zh) 用于治疗阿尔茨海默氏病的苄醚和苄氨基β－分泌酶抑制剂
CN1960990A (zh) 作为用于治疗或预防糖尿病的二肽基肽酶－ⅳ抑制剂的环己基丙氨酸衍生物
CN1863770A (zh) 具有杂环取代基的环胺base－1抑制剂
CN1906160A (zh) 咪唑衍生物及其制备方法和其应用
CN1124960A (zh) 作为5-ht/a和/或5-ht2配体的吲哚衍生物
CN1678317A (zh) 用作治疗呕吐、抑郁症、焦虑症和咳嗽的神经激肽－1(nk－1)拮抗剂的1－酰氨基－4－苯基－4－苄氧基甲基－哌啶衍生物和相关化合物
CN1564685A (zh) 吡咯烷酮衍生物
CN1653046A (zh) 8－氮杂前列腺素衍生化合物以及包含该化合物作为活性成分的药物
CN1898199A (zh) 用于治疗阿尔茨海默病的苯基酰胺和吡啶基酰胺类β－分泌酶抑制剂
CN1133593A (zh) 用于治疗的哌嗪化合物
CN1305993A (zh) 用作氧化氮合成酶抑制剂的环状脒基制剂
CN1906164A (zh) 组织蛋白酶半胱氨酸蛋白酶抑制剂
CN1886416A (zh) Comt抑制剂
CN1255161A (zh) 蛋白酶抑制剂
CN1079396C (zh) 用作选择性凝血酶抑制剂的芳族脒衍生物
CN1402710A (zh) 抗细小核糖核酸病毒化合物和组合物,其药用,和其合成原料
CN1610678A (zh) 吡咯烷酮羧酰胺
CN1225465C (zh) 新化合物
CN1431995A (zh) 抗细小rna病毒的化合物与组合物,它们的药物用途,以及用于其合成的物质
CN1950337A (zh) 用于治疗阿尔茨海默病的（4,5,6,7－四氢－1－h－吲哚－7－基）乙酸衍生物
HK1088006A (en) 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1078570

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070307

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1078570

Country of ref document: HK